

“Melanoma Bridge 2018”
Naples – November 29th – December 1st 2018

PRELIMINARY PROGRAM

***Not included in the CME accredited program*

**invited faculty*

November 29th (Thursday)

17:00 18:00 *Registration***

18:00 18.30 *Opening Session Lecture***, Magdalena Thurin

November 30th (Friday)

9:00 9:30 *Registration***

Session - Melanoma as a model system

Chairperson: Giuseppe Masucci, Olivier Michielin

9:30 9:50 Neoadjuvant and adjuvant, Sanjiv Agarwala

9:50 10:10 Biomarkers in immunotherapy of melanoma: an update, Claus Garbe

10:10 10:30 Combining MAPK and PD-1/L1 inhibitors- lessons from patients and mice, Roger Lo

10:30 10:50 Clinical evidence emerging from radiation and Immunotherapy, Silvia Formenti

10:50 11:10 Discussion on melanoma as a model system, Giuseppe Masucci, Olivier Michielin

11:10 11:25 *Break***

11:25 12:25 *Oral Communications***

12:25 13:25 *Symposium Title to be defined** - Sponsored by MSD*

Paolo A. Ascierto, Mario Mandalà

13:25 14:10 *Lunch***

Session - Mechanisms of resistance and drivers of response

Chairpersons: Gerardo Botti, Giuseppe Palmieri

14:10 15:10 Symposium

15:10 15:30 Exosomes, Soldano Ferrone

15:30 15:50 Microbiota, Laurence Zitvogel

15:50 16:10 Title to be defined, Thomas Gajewski

16:10 16:30 Title to be defined, Abi Diab

16:30 16:50 Discussion on mechanisms of resistance and drivers of response, Gerardo Botti, Giuseppe Palmieri

3P Solution S.r.l. a socio unico. Sede Legale: via Marradi 3, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426. Provider Standard n. 327 dal 15 ottobre 2012

Sistema di gestione per la qualità secondo la Norma **UNI EN ISO 9001:2015** per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità. Certificazione CSQA n. 23887



- 16:50 17:05 *Break***
- 17:05 18:05 *Oral Communications***
- 18:05 18:20 Conclusions, Gerardo Botti, Giuseppe Palmieri

December 1st (Saturday)

Session - Emerging strategies

Chairpersons: Corrado Caracò, Alfredo Budillon

- 9:30 9:50 Translational research in the therapeutic landscape for metastatic melanoma, Reinhard Dummer
- 9:50 10:10 Title to be defined, Igor Puzanov
- 10:10 10:30 Advancing the understanding and treatment of melanoma CNS metastases, Michael Davies
- 10:30 10:50 Emerging strategies for combination immunotherapy in melanoma, Jason Luke
- 10:50 11:10 Discussion
- 11:10 11:40 Lecture – Target therapy and Immunotherapy: rational for combination and future perspectives, Paolo A. Ascierto
- 11:40 11:55 *Break***
- 11:55 12:55 *Oral Communications***
- 12:55 13:55 Symposium – IO adjuvant therapy and novel combination
Chairperson: Paolo A. Ascierto
- 12:55 A new paradigm: IO as adjuvant, Omid Hamid
- 13:15 Novel combination strategies, Paolo A. Ascierto
- 13:35 Discussion on IO adjuvant therapy and novel combination, Paolo A. Ascierto, Omid Hamid
- 13:55 14:30 *Lunch***

Session - Great Debate

Chairpersons: Alessandro Testori, Franco Perrone

14:30 15:30 Symposium

- 15:30 16:00 Is OS still the main endpoint? Yes or no - Alexander Eggermont, Paolo Bruzzi
- 16:00 16:10 Discussion on Is OS still the main endpoint? Alessandro Testori, Franco Perrone, Alexander Eggermont, Paolo Bruzzi
- 16:10 16:40 Is anti CTLA-4 still the good drug to combine with anti PD-L1? Yes or no - Paolo A. Ascierto, Omid Hamid
- 16:40 16:50 Discussion on Is anti CTLA-4 still the good drug to combine with anti PD-L1?, Alessandro

3P Solution S.r.l. a socio unico. Sede Legale: via Marradi 3, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426. Provider Standard n. 327 dal 15 ottobre 2012

Sistema di gestione per la qualità secondo la Norma **UNI EN ISO 9001:2015** per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità. Certificazione CSQA n. 23887



		Testori, Franco Perrone, Paolo A. Ascierto, Omid Hamid
16:50	17:20	Adjuvant vs neoadjuvant - Alexander van Akkooi, John Kirkwood
17:20	17:30	Discussion on Adjuvant vs neoadjuvant, Alessandro Testori, Franco Perrone Alexander van Akkooi, John Kirkwood
17:30	17:50	Conclusions, Paolo A. Ascierto, Corrado Caracò, Igor Puzanov

Presidency

Paolo A. Ascierto	Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy
Corrado Caracò	Director of Department Melanoma, Soft Tissue, Muscle-Skeletal and Head-Neck, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy
Igor Puzanov	Associate Professor of Medicine, Associate Director of Phase I Drug Development, Director, Melanoma Clinical Research, Director of Early Clinical Trials and Developmental Therapeutics, Director of Melanoma Program, Professor of Medicine and Oncology at Roswell Park Cancer Institute in Buffalo, New York

Scientific Board

Sanjiv Agarwala	Chief of Medical oncology and Hematology, St. Luke’s University Hospital and Temple University, Bethlehem, Pennsylvania
Paolo A. Ascierto	Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy
Carlo Bifulco	Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, Oregon
Lisa H. Butterfield	SITC, University of Pittsburgh, Pennsylvania, US
Corrado Caracò	Director of Department Melanoma, Soft Tissue, Muscle-Skeletal and Head-Neck, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy
Reinhard Dummer	Professor of Dermatology, University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland
Bernard A. Fox	Chief of the Laboratory of Molecular and Tumor Immunology, Oregon Health and Science University, Providence Cancer Center, Portland Medical Center, Oregon
Jerome Galon	Research Director, National Institute of Health and Medical Research (INSERM), Paris, France
Claus Garbe	University Professor of Dermatology, Division of Dermatologic Oncology Department of Dermatology Eberhard Karls University Tuebingen, Germany
Giuseppe Masucci	Professor, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden

3P Solution S.r.l. a socio unico. Sede Legale: via Marradi 3, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426. Provider Standard n. 327 dal 15 ottobre 2012
Sistema di gestione per la qualità secondo la Norma **UNI EN ISO 9001:2015** per progettazione ed erogazione dei servizi per la
Formazione Continua in Sanità. Certificazione CSQA n. 23887

Michael Postow	Memorial Sloane Kettering Cancer Center, New York, New York
Igor Puzanov	Associate Professor of Medicine, Associate Director of Phase I Drug Development, Director, Melanoma Clinical Research, Director of Early Clinical Trials and Developmental Therapeutics, Director of Melanoma Program, Professor of Medicine and Oncology at Roswell Park Cancer Institute in Buffalo, New York
Magdalena Thurin	Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland

Invited Faculty

Sanjiv Agarwala	Chief of Medical oncology and Hematology, St. Luke's University Hospital and Temple University, Bethlehem, Pennsylvania
Paolo A. Ascierto	Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy
Gerardo Botti	Head of the Department of Diagnostic Pathology, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy
Paolo Bruzzi	Clinical Epidemiology Unit Director, University Hospital "San Martino", Genova, Italy
Alfredo Budillon	Staff Member and Senior Scientist of Molecular Biology and Viral Oncology Unit National, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy
Corrado Caracò	Director of Department Melanoma, Soft Tissue, Muscle-Skeletal and Head-Neck, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy
Michael Davies	Associate Professor, Department of Melanoma Medical Oncology, Department of Systems Biology, University of Texas MD Anderson Cancer Center, Texas, US
Adi Diab	Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, US
Reinhard Dummer	Professor of Dermatology, University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland
Alexander Eggermont	Director, Gustave Roussy Cancer Campus Grand Paris Villejuif, France
Soldano Ferrone	Massachusetts General Hospital, Boston, Massachusetts, US
Silvia Formenti	Department of Radiation Oncology - Weill Cornell Medical College, NY
Thomas F. Gajewski	Oncology and Immunology Professor, Department of Pathology and Department of Medicine, Section of Hematology/Oncology, Chicago, Illinois, US
Claus Garbe	University Professor of Dermatology, Division of Dermatologic Oncology Department of Dermatology Eberhard Karls University Tuebingen, Germany
Omid Hamid	Director, Clinical Research and Immunotherapy at The Angeles Clinic and Research Institute, Los Angeles, CA
John M. Kirkwood	Usher Professor of Medicine, Dermatology and Translational Science and Director of Melanoma and Skin Cancer Program, Department of Medicine,

3P Solution S.r.l. a socio unico. Sede Legale: via Marradi 3, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426. Provider Standard n. 327 dal 15 ottobre 2012
Sistema di gestione per la qualità secondo la Norma **UNI EN ISO 9001:2015** per progettazione ed erogazione dei servizi per la
Formazione Continua in Sanità. Certificazione CSQA n. 23887



	Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, US
Roger Lo	Melanoma Clinic in Dermatology Member, Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA, Los Angeles, California, US
Jason Luke	Assistant Professor of Medicine at University of Chicago Medicine, University of Chicago Medicine, Rosalind Franklin University of Medicine and Science, Chicago, Illinois
Olivier Michielin	Analytical Oncology Division Director, Oncology Department UNIL-CHUV, Lausanne, Suisse
Giuseppe Masucci	Professor, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
Giuseppe Palmieri	Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council, Sassari, Italy
Francesco Perrone	USC Director, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy
Igor Puzanov	Associate Professor of Medicine, Associate Director of Phase I Drug Development, Director, Melanoma Clinical Research, Director of Early Clinical Trials and Developmental Therapeutics, Director of Melanoma Program, Professor of Medicine and Oncology at Roswell Park Cancer Institute in Buffalo, New York
Alessandro Testori	Chairman Gruppo Chirurgico EORTC Melanoma Group, EORTC Melanoma Group Brussels, Belgium
Magdalena Thurin	Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland
Alexander van Akkooi	Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
Laurence Zitvogel	Institut Gustave Roussy, Villejuif, Paris-Sud, France

SCIENTIFIC RATIONAL

Metastatic melanoma represents a challenging clinical situation due, until relatively recently, to a paucity of effective treatment options. Melanoma treatment landscape changed in 2011 with the approval of the first

3P Solution S.r.l. a socio unico. Sede Legale: via Marradi 3, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426. Provider Standard n. 327 dal 15 ottobre 2012

Sistema di gestione per la qualità secondo la Norma **UNI EN ISO 9001:2015** per progettazione ed erogazione dei servizi per la Formazione Continua in Sanità. Certificazione CSQA n. 23887



anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival. Since then, improved understanding of the tumor microenvironment and tumor immuno-evasion strategies has resulted in different approaches to target and harness the immune response. Approval of new immune- and target-therapies have further improved outcomes for patients with advanced melanoma. The new therapies offer the opportunity for various approaches with distinct modes of action being used in combination with one another, as well as combined with other treatment modalities such as radiotherapy, electrochemotherapy and surgery.

However, many questions still remain unanswered, beginning with the identification of melanoma patients who will derive most benefit from different treatments and on the biomarkers that can be employed to help select patients for treatment. Other pending questions that will drive the discussion at Melanoma Bridge are:

- Is melanoma a model system in cancer treatment?
- What do we know of the mechanisms of resistance and of drivers of response?
- Which are the most valuable emerging strategies?

Conclusions will be drawn after the “Great Debate” session, where counterpoint views from leading experts on specific controversial clinical issues will be presented and discussed: (1) whether overall survival is still the main endpoint; (2) whether anti CTLA-4 is still the good drug to combine with anti PD-L1 (programmed death ligand 1); (3) whether neo-adjuvant should be preferred over adjuvant therapy.

Presidents of the event are Paolo A. Ascierto (INT, Naples, Italy), Igor Puzanov (Roswell Park Cancer Center, New York), and Corrado Caracò (INT, Naples, Italy), who will gather with the international faculty members in an interactive atmosphere which stimulates discussion and exchange of their experience regarding the most recent advances in research and clinical management of melanoma patients.

3P Solution S.r.l. a socio unico. Sede Legale: via Marradi 3, 20123 Milano.

Capitale sociale: 10.000,00€ iv. P.IVA/CF 06860060968 Iscrizione REA MI n.1919426. Provider Standard n. 327 dal 15 ottobre 2012
Sistema di gestione per la qualità secondo la Norma **UNI EN ISO 9001:2015** per progettazione ed erogazione dei servizi per la
Formazione Continua in Sanità. Certificazione CSQA n. 23887

